Stifel Financial Corp Purchases 50,637 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Stifel Financial Corp increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 82.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 112,102 shares of the company's stock after acquiring an additional 50,637 shares during the quarter. Stifel Financial Corp's holdings in Elanco Animal Health were worth $1,647,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Canada Pension Plan Investment Board bought a new stake in shares of Elanco Animal Health during the 2nd quarter valued at $55,599,000. Magnetar Financial LLC lifted its position in Elanco Animal Health by 61.2% during the second quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company's stock worth $120,298,000 after purchasing an additional 3,164,350 shares during the period. Point72 Asset Management L.P. acquired a new stake in Elanco Animal Health during the third quarter worth about $19,708,000. Assenagon Asset Management S.A. increased its holdings in Elanco Animal Health by 363.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company's stock valued at $22,748,000 after buying an additional 1,214,123 shares during the period. Finally, Great Lakes Advisors LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at approximately $16,043,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Trading Down 1.6 %

Shares of NYSE:ELAN traded down $0.19 during midday trading on Friday, hitting $11.63. 9,435,554 shares of the stock were exchanged, compared to its average volume of 4,797,913. The business's 50-day moving average price is $12.96 and its 200 day moving average price is $14.15. The stock has a market capitalization of $5.75 billion, a price-to-earnings ratio of 29.08, a P/E/G ratio of 2.03 and a beta of 1.41. Elanco Animal Health Incorporated has a 12 month low of $11.40 and a 12 month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company's revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.18 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. UBS Group initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a "buy" rating and a $18.00 price target on the stock. Barclays raised their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Morgan Stanley lowered Elanco Animal Health from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Leerink Partners assumed coverage on Elanco Animal Health in a research note on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $16.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.